CO2021008018A2 - Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta - Google Patents

Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta

Info

Publication number
CO2021008018A2
CO2021008018A2 CONC2021/0008018A CO2021008018A CO2021008018A2 CO 2021008018 A2 CO2021008018 A2 CO 2021008018A2 CO 2021008018 A CO2021008018 A CO 2021008018A CO 2021008018 A2 CO2021008018 A2 CO 2021008018A2
Authority
CO
Colombia
Prior art keywords
modulating
activity
methods
compositions
short chain
Prior art date
Application number
CONC2021/0008018A
Other languages
English (en)
Inventor
Sanford Markowitz
Joseph Ready
Ii Stephen L Gwaltney
Monika Antczak
Original Assignee
Univ Case Western Reserve
Univ Texas
Rodeo Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve, Univ Texas, Rodeo Therapeutics Corp filed Critical Univ Case Western Reserve
Publication of CO2021008018A2 publication Critical patent/CO2021008018A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Los compuestos y métodos para modular la actividad de 15-PGDH, modular los niveles de prostaglandina tisular, tratar enfermedades, trastornos de enfermedades o afecciones donde se desea modular la actividad de 15-PGDH y/o los niveles de prostaglandinas incluyen inhibidores de 15-PGDH descritos en el presente documento.
CONC2021/0008018A 2018-11-21 2021-06-18 Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta CO2021008018A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770571P 2018-11-21 2018-11-21
PCT/US2019/062686 WO2020106998A1 (en) 2018-11-21 2019-11-21 Compositions and methods of modulating short-chain dehydrogenase activity

Publications (1)

Publication Number Publication Date
CO2021008018A2 true CO2021008018A2 (es) 2021-09-20

Family

ID=70774671

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008018A CO2021008018A2 (es) 2018-11-21 2021-06-18 Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta

Country Status (20)

Country Link
US (1) US20230039604A1 (es)
EP (1) EP3883577A4 (es)
JP (1) JP2022507888A (es)
KR (1) KR20210119954A (es)
CN (1) CN113507931A (es)
AU (1) AU2019384821A1 (es)
BR (1) BR112021009832A2 (es)
CA (1) CA3120858A1 (es)
CL (1) CL2021001321A1 (es)
CO (1) CO2021008018A2 (es)
CR (1) CR20210328A (es)
EA (1) EA202191422A1 (es)
IL (1) IL283168A (es)
JO (1) JOP20210115A1 (es)
MA (1) MA55147A (es)
MX (1) MX2021005982A (es)
PE (1) PE20212246A1 (es)
PH (1) PH12021551169A1 (es)
SG (1) SG11202105345TA (es)
WO (1) WO2020106998A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2018187810A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
TW202208376A (zh) * 2020-05-20 2022-03-01 美國凱斯西方瑞瑟夫大學 調節短鏈脫氫酶活性之組成物及方法
WO2023137353A1 (en) * 2022-01-14 2023-07-20 Ventyx Biosciences, Inc. 15-pgdh inhibitors
WO2023143432A1 (zh) * 2022-01-28 2023-08-03 赛诺哈勃药业（成都）有限公司 一种调控15-pgdh活性的化合物及其制备方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
WO2024017366A1 (zh) * 2022-07-22 2024-01-25 赛诺哈勃药业（成都）有限公司 一种调控15-pgdh活性的化合物及其制备方法
WO2024099429A1 (zh) * 2022-11-11 2024-05-16 赛诺哈勃药业（成都）有限公司 一种调控15-pgdh活性的化合物及其制备方法
WO2024104317A1 (zh) * 2022-11-14 2024-05-23 武汉人福创新药物研发中心有限公司 抑制15-pgdh的化合物及其用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382248A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US4910226A (en) 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
LU87308A1 (fr) 1988-08-01 1990-03-13 Oreal Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
FR2651122B1 (fr) 1989-08-29 1994-10-28 Oreal Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3.
US5480913A (en) 1989-09-27 1996-01-02 Arch Development Corporation Anti-androgen compounds
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
FR2662607B1 (fr) 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
FR2678929A1 (fr) 1991-07-11 1993-01-15 Oreal Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde.
FR2683531B1 (fr) 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
US5516779A (en) 1994-06-08 1996-05-14 Merck & Co., Inc. 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5807895A (en) 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
US5529769A (en) 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
FR2732597B1 (fr) 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
US5631282A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
JPH10215356A (ja) 1996-11-27 1998-08-11 Fuji Photo Film Co Ltd 再プリント用写真画像データの保管方法およびシステム
WO1998033497A1 (en) 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
WO1999031125A1 (en) 1997-12-12 1999-06-24 University Of Southern California Wound healing compositions
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CN1366458A (zh) 2000-03-31 2002-08-28 东丽株式会社 毛发生长和毛发形成调节剂
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
WO2004073594A2 (fr) 2003-02-12 2004-09-02 L'oreal Utilisation d’un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US20070071699A1 (en) 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20070078175A1 (en) 2005-10-05 2007-04-05 L'oreal Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof
WO2010077101A2 (ko) 2008-12-30 2010-07-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9801863B2 (en) * 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
AU2014342811B2 (en) * 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
EP3267995A4 (en) * 2015-03-08 2019-02-27 Case Western Reserve University INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF FIBROSIS
CA2982784A1 (en) * 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2018017582A1 (en) * 2016-07-18 2018-01-25 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
WO2018102552A1 (en) * 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2018187810A1 (en) * 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
WO2018218251A1 (en) * 2017-05-26 2018-11-29 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2021134242A (ja) 2020-02-25 2021-09-13 株式会社アイティー技研 鉱物油精製方法及び装置
JP2022100091A (ja) 2020-12-23 2022-07-05 株式会社リコー 画像処理装置、画像処理システム、方法およびプログラム

Also Published As

Publication number Publication date
PE20212246A1 (es) 2021-11-24
EP3883577A1 (en) 2021-09-29
EA202191422A1 (ru) 2021-10-21
US20230039604A1 (en) 2023-02-09
CA3120858A1 (en) 2020-05-28
SG11202105345TA (en) 2021-06-29
JOP20210115A1 (ar) 2023-01-30
PH12021551169A1 (en) 2021-11-08
CR20210328A (es) 2021-12-02
AU2019384821A1 (en) 2021-06-10
EP3883577A4 (en) 2022-06-15
WO2020106998A1 (en) 2020-05-28
KR20210119954A (ko) 2021-10-06
CN113507931A (zh) 2021-10-15
JP2022507888A (ja) 2022-01-18
MA55147A (fr) 2021-09-29
IL283168A (en) 2021-06-30
BR112021009832A2 (pt) 2021-08-17
CL2021001321A1 (es) 2022-04-01
MX2021005982A (es) 2021-09-23

Similar Documents

Publication Publication Date Title
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
UY39225A (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
ECSP21086429A (es) Moduladores de la vía integrada del estrés
MX2020004555A (es) Moduladores de la vía de estrés integrada.
MX2020004538A (es) Moduladores de la vía de estrés integrada.
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
MX2020004558A (es) Moduladores de la vía de estrés integrada.
MX2020004551A (es) Moduladores de la vía de estrés integrada.
MX2020004557A (es) Moduladores de la vía de estrés integrada.
MX2020004534A (es) Moduladores de la vía integrada del estrés.
EA201790998A1 (ru) Иммуннорегуляторные агенты
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
DOP2016000120A (es) Nuevos inhibidores de dgat2
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
MX2022002443A (es) Compuestos inhibidores de perk.
CO2020014069A2 (es) Sales de meglumina de tienopirimidinas
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2
EA202091110A1 (ru) Модуляторы интегрированного стресса